Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502857 | 1.00 | NAMPT (0.46) | NAMPTALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL503088 | 0.86 | RAB9A (0.52) | NAMPTALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL30373982 | 0.84 | RORC (0.44) | POLBKMT2ASMN1; SMN2 | |
| SCHEMBL29538087 | 0.81 | MAPT (0.54) | NAMPT | |
| SCHEMBL12609789 | 0.80 | HTT (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL12609787 | 0.80 | HTT (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL6917552 | 0.78 | NAMPT (0.45) | NAMPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25489259 | 0.78 | NAMPT (0.43) | NAMPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1990308 | 0.77 | SMN1; SMN2 (0.42) | NAMPTSMN1; SMN2 | |
| SCHEMBL1990310 | 0.77 | SMN1; SMN2 (0.42) | NAMPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132136-B2 | Pharmaceutical combination | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2600853-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016879-A1 | COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | SEMINIS VEGETABLE SEEDS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028964-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | NAMPT 1784/4885ALDH1A1 271/4885POLB 3977/4885 |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | NAMPT 1784/4885ALDH1A1 271/4885POLB 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.